Enterprise Value

12.78B

Cash

1.168B

Avg Qtr Burn

N/A

Short % of Float

5.60%

Insider Ownership

2.59%

Institutional Own.

93.07%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rylaze (JZP-458) Details
Acute lymphoblastic leukemia

Approved

Quarterly sales

Xywav (JZP-258) (oxybate salts) Details
EDS in Idiopathic Hypersomnia

Approved

Quarterly sales

EPIDIOLEX® (cannabidiol) Details
Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome

Approved

Quarterly sales

Zepzelca (Lurbinectedin) Details
Cancer, Small cell lung cancer

Approved

Quarterly sales

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Rare genetic disease, Neurological disorder, Epilepsy, Seizures

Phase 3

Data readout

Zepzelca +Tecentriq Details
Cancer, Small cell lung cancer

Phase 3

Data readout

Phase 2b

Data readout

Zanidatamab Details
Cancer, HER2-expressing cancers

Phase 2b

Update

CBDV (Cannabidivarin /GWP42006) Details
Epilepsy, Autism spectrum disorders

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Zanidatamab combo w/ chemo Details
Cancer, HER2-expressing cancers

Phase 2

Data readout

JZP-150 (FAAH inhibitor) Details
Post-traumatic stress disorder

Big Mover™

Susp. Mover™

Phase 2

Data readout

Zepzelca (Lurbinectedin) Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Zanidatamab combo w/ docetaxel Details
Cancer, HER2-expressing cancers

Phase 1/2

Interim update

JZP351 (CPX-351) Details
Blood cancer, Cancer, Acute myeloid leukemia

Phase 1b

Data readout

JZP-441 (orexin-2 receptor agonist) Details
Sleeping disorder, EDS in Idiopathic Hypersomnia , Narcolepsy

Phase 1

Data readout

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder

Failed

Discontinued

Nabiximols Details
Multiple sclerosis

Failed

Discontinued